1. What Is the Oncogenomics Market?
The Oncogenomics Market covers tumor WGS, exome sequencing, cancer gene expression profiling, and somatic mutation analysis. TMB assessment platforms and cancer genomic data repositories are core market components. These technologies characterize the full genomic landscape of cancers for research and clinical applications. Core applications include cancer driver gene discovery, tumor evolution tracking, immunotherapy biomarker identification, and targeted therapy companion diagnostic development. Market dynamics reflect FDA-approved companion diagnostic expansion, TCGA and PCAWG data mining, and TMB adoption. Multi-omic cancer atlas programs and single-cell tumor profiling further accelerate market growth.
2. Oncogenomics Market Size & Forecast
3. Emerging Technologies
- HRD homologous recombination deficiency scoring for PARP inhibitor patient selection are advancing. Growing clinical adoption is driven by olaparib, niraparib, and rucaparib companion diagnostic requirements.
- Spatial tumor genomics mapping subclone distribution and immune infiltration patterns are advancing. Growing pharmaceutical use is driven by spatial resistance and IO biomarker discovery programs.
- Multi-omic tumor profiling combining WGS, RNA-seq, proteomics, and methylation are advancing. Growing adoption is driven by comprehensive cancer molecular characterization for drug development programs.
- Tumor organoid drug sensitivity assays linked to tumor WGS for ex-vivo personalized oncology are advancing. Growing clinical interest is driven by precision oncology treatment matching beyond genomic biomarkers.
Similar technologies are also transforming adjacent markets. Learn more in our Whole Genome Sequencing Market.
4. Key Market Opportunity
The primary opportunity in the Oncogenomics Market is companion diagnostic TMB and HRD panel adoption. Multi-omic tumor atlas programs create pharmaceutical drug discovery data mining platform revenue. Single-cell tumor heterogeneity profiling creates a research and clinical market for scRNA-seq platforms. Asia Pacific oncogenomics market expansion in China and Japan creates geographic opportunity.
5. Top Companies in the Oncogenomics Market
The following organisations hold leading positions in the Oncogenomics Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Foundation Medicine (Roche)
- Tempus
- Caris Life Sciences
- Guardant Health
- Illumina (TSO500, DRAGEN Somatic)
- Pacific Biosciences (tumor WGS)
- Broad Institute (cancer genomics)
- NovaBay (cancer genome tools)
- Sophia Genetics
- Personal Genome Diagnostics
6. Market Segmentation
The Oncogenomics Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Type | Tumor WGSCancer Gene PanelsRNA Expression ProfilingSingle-Cell Tumor GenomicsctDNA |
| By Application | Companion Diagnostic DevelopmentCancer Driver DiscoveryIO BiomarkerTumor Evolution |
| By End User | Pharmaceutical Drug DiscoveryAcademic Cancer ResearchClinical LabsBiotech |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Oncogenomics Market trajectory over the forecast period:
Tumor Mutational Burden Is Established as a Pan-Cancer Immunotherapy Response Biomarker.FDA approved pembrolizumab for TMB-high tumors as the first tissue-agnostic TMB companion diagnostic indication. TMB measurement from comprehensive cancer gene panels is a standard clinical oncogenomics application. Foundation Medicine F1CDx and Illumina TSO500 provide validated TMB measurements meeting FDA standards. TMB-guided immunotherapy prescribing is creating non-discretionary cancer panel sequencing demand at oncology centers.
Multi-Omic Cancer Atlas Programs Are Building Comprehensive Molecular Cancer Reference Databases.TCGA catalogued mutations, expression, methylation, and copy number alterations across 33 cancer types. PCAWG expanded cancer whole genome analysis to 2,658 donors across 38 tumor types. These atlas datasets enable cancer genomics drug target discovery through data mining without new sequencing. Pharmaceutical companies mine TCGA and PCAWG to identify genomic alterations associated with drug response.
Single-Cell Tumor Genomics Is Revealing Intratumoral Heterogeneity and Drug Resistance Mechanisms.ScRNA-seq and single-cell DNA sequencing of tumors profile genetic diversity across thousands of individual cancer cells. This heterogeneity data explains variable drug response and identifies resistant subclone populations. Pharmaceutical programs use single-cell tumor data to design combination therapies eliminating resistant subclones. Single-cell oncogenomics is advancing from research tool toward clinical tumor characterization application.
For related market intelligence, see the Targeted Sequencing Market.
8. Segmental Analysis
By type, the Cancer Gene Panel segment dominated the Oncogenomics Market in 2025. FDA-approved companion diagnostic panels create the largest revenue category through mandatory clinical testing. The Single-Cell Tumor Genomics segment is fastest-growing, driven by intratumoral heterogeneity research adoption.
9. Regional Analysis
Regional demand patterns across the Oncogenomics Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Oncogenomics Market in 2025 with a market share of 44.0%. The region leads cancer genomics companion diagnostic development and FDA regulatory approval. Foundation Medicine, Guardant Health, and Tempus represent a dominant US cancer genomics company cluster. Moreover, NCI-funded cancer genomics programs including TCGA and Cancer Moonshot drive research demand. In addition, US pharmaceutical companies lead multi-omic tumor characterization drug discovery investment. CDx leadership and cancer program funding sustain North American dominance through the forecast period.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR of 18.90% in the Oncogenomics Market through 2034. China's cancer genomics market is growing rapidly with companion diagnostic adoption at major cancer hospitals. Japan's established clinical cancer genomics panel adoption and pharmaceutical investment create strong demand. Moreover, South Korea's national cancer precision medicine program drives genomics panel procurement. Cancer genomics adoption and pharmaceutical investment position Asia Pacific for sustained Oncogenomics Market outperformance.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Oncogenomics Market was valued at USD 3.20 Bn in 2025 and is projected to reach USD 10.00 Bn by 2034, growing at a CAGR of 13.50% over the 2026–2034 forecast period.
The Oncogenomics Market is projected to grow at a CAGR of 13.50% from 2026 to 2034.
North America dominated the Oncogenomics Market in 2025 with a market share of 44.0%.
The leading companies in the Oncogenomics Market include Foundation Medicine (Roche), Tempus, Caris Life Sciences, Guardant Health, Illumina (TSO500, DRAGEN Somatic), Pacific Biosciences (tumor WGS), Broad Institute (cancer genomics), NovaBay (cancer genome tools), Sophia Genetics, Personal Genome Diagnostics.
Tumor mutational burden is established as a pan-cancer immunotherapy response biomarker.
By type, the Cancer Gene Panel segment dominated the Oncogenomics Market in 2025.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.